HILDEN, Germany and GERMANTOWN, Maryland, March 11, 2014 /PRNewswire/ --
- GeneGlobe web portal now powered by QIAGEN's Ingenuity Target Explorer, linking assay search and selection tools with curated biological context
- Enhanced search results save time and help scientists design cost-effective studies
- GeneGlobe portal provides access to more than 31 million PCR and NGS assay options available through QIAGEN, targeting any gene or pathway of interest
- Findings include access to extensive biomedical literature on genes and pathways
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced new capabilities for GeneGlobe, the Company's Genes & Pathways web portal providing access to biological assays. In its new version, GeneGlobe integrates biological knowledge through its Ingenuity Target Explorer bioinformatics application with GeneGlobe's extensive library of wet lab assay solutions. By linking biological interpretation and references with the relevant laboratory assays, GeneGlobe creates a new dimension of utility for experimental design, assay selection and data analysis to accelerate life science research.
QIAGEN's GeneGlobe is a web-based solution enabling researchers to search and select from more than 31 million PCR assay kits and NGS assay panel products. It includes genome-wide assay solutions for 28 species with any gene or pathway of interest. The search, selection and interpretation solutions create a user experience that precisely identifies assays and reagents that fit a life science researcher's experimental design and adds a comprehensive set of interpretation solutions. GeneGlobe also supports scientists with additional resources such as Pathway Central, Data Analysis Center, Custom Assay Design Tools and the Plate Designer.
"GeneGlobe is designed to provide significant value to scientists as it allows fast and economical access to the power of big data and the promise of exponentially increasing genomic knowledge", said Dr. Dietrich Hauffe, Senior Vice President, Life Sciences Business Area. "The new version of GeneGlobe integrates our Ingenuity Target Explorer web tools to help researchers quickly gain biological insights from the most current biomedical literature and databases as they design their experiments - with direct access to wet lab solutions (PCR assays and GeneRead NGS gene panels) relevant to the diseases and pathways they are studying."
The Ingenuity Target Explorer tools in GeneGlobe deliver three key functionalities to help life science researchers:
- Summary - This section offers information on each gene of interest, drawing on multiple databases to describe features such as molecular function, cellular localization and relevant publications. With a dynamically updating knowledge base, this summary ensures that the user is directed to relevant research findings in even very current biomedical literature.
- Interaction Network - This section includes the listing of genes or molecules that impact each user-selected target, including supporting evidence for the interactions. With built-in biological filters, this interaction network can display interactions matching a disease or tissue-specific context selected by the researcher conducting the study.
- Pathways - This section places each gene or molecule in the context of a biological process, enabling the scientist to view various pathway maps and gain a systems overview to help define the best experimental approach. The dynamically updated maps also provide links to supporting evidence in the biomedical literature.
To view and interact with new QIAGEN GeneGlobe, please visit http://www.geneglobe.com.
QIAGEN N.V., a Netherlands holding company, is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular information. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are then used to make these isolated biomolecules visible and ready for interpretation. QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to customers through four customer classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of December 31, 2013, QIAGEN employed approximately 4,000 people in more than 35 locations worldwide. Further information can be found at http://www.QIAGEN.com/.
Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results, including without limitation its expected operating results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products in applied testing, personalized healthcare, clinical research, proteomics, women's health/HPV testing and nucleic acid-based molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products, the consummation of acquisitions, and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).
Contacts: Public Relations: Dr. Thomas Theuringer Director Public Relations +49-2103-29-11826 +1-240-686-7425 Email: email@example.com http://www.twitter.com/qiagen pr.qiagen.com Investor Relations: John Gilardi Vice President Corporate Communications and Investor Relations +49-2103-29-11711 +1-240-686-2222 Email: firstname.lastname@example.org ir.qiagen.com